| Variant | Gene | Disease | Risk Allele | Score vda | Association Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
0.700 | GeneticVariation | UNIPROT | |||||||||||
|
|
0.800 | GeneticVariation | UNIPROT | |||||||||||
|
|
0.730 | GeneticVariation | UNIPROT | |||||||||||
|
|
0.700 | GeneticVariation | UNIPROT | |||||||||||
|
|
0.700 | GeneticVariation | UNIPROT | |||||||||||
|
|
0.700 | GeneticVariation | UNIPROT | |||||||||||
|
|
0.700 | GeneticVariation | UNIPROT | |||||||||||
|
|
0.700 | GeneticVariation | UNIPROT | |||||||||||
|
|
0.700 | GeneticVariation | UNIPROT | |||||||||||
|
|
0.700 | GeneticVariation | UNIPROT | |||||||||||
|
|
0.700 | GeneticVariation | UNIPROT | |||||||||||
|
|
0.700 | GeneticVariation | UNIPROT | |||||||||||
|
|
0.700 | GeneticVariation | UNIPROT | |||||||||||
|
|
0.700 | GeneticVariation | UNIPROT | |||||||||||
|
|
0.700 | GeneticVariation | UNIPROT | |||||||||||
|
|
0.700 | GeneticVariation | UNIPROT | |||||||||||
|
|
0.700 | GeneticVariation | UNIPROT | |||||||||||
|
|
0.700 | GeneticVariation | UNIPROT | |||||||||||
|
|
0.700 | GeneticVariation | UNIPROT | |||||||||||
|
|
0.700 | GeneticVariation | UNIPROT | |||||||||||
|
|
0.700 | GeneticVariation | UNIPROT | |||||||||||
|
|
0.700 | GeneticVariation | UNIPROT | National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. | 19042984 | 2008 |
||||||||
|
|
0.700 | GeneticVariation | UNIPROT | Screening for ovarian cancer: U.S. Preventive Services Task Force reaffirmation recommendation statement. | 22964825 | 2012 |
||||||||
|
|
0.700 | GeneticVariation | UNIPROT | NSGC practice guideline: risk assessment and genetic counseling for hereditary breast and ovarian cancer. | 23188549 | 2013 |
||||||||
|
|
0.700 | GeneticVariation | UNIPROT |